Sebi will act against pharma cos in case of non-disclosure of material information, says Tyagi

Mumbai: Markets regulator Sebi on Thursday said it would take action against pharma companies if they are found not sharing information on material events like inspections and reports by the US FDA.

“It is necessary to share material information even now. If the US FDA (Food and Drug Administration) has taken any action against them (pharmaceutical companies) and they are not disclosing it, if that comes before us, we will take action,” Sebi chairman Ajay Tyagi told reporters here.

He was replying to a specific question pertaining to pharma companies not disclosing actions by drug regulators in foreign markets like the US FDA undertaking inspections of their facilities and passing orders.

There have allegedly been instances of such happenings not being properly disclosed to the investors.

Tyagi said such information that constitutes to be “material information” should be shared with the stock exchanges immediately by the respective companies.

India is one of the world’s biggest pharma exporters and many of the domestic players in the sector are listed on the exchanges.

  • Related Posts

    8 Women Develop Complications Post C-Section, 2 Critical

    Close on the heels of maternal deaths and kidney-related complications reported in Kota and Bikaner following caesarean deliveries, a similar case has surfaced at Paota District Hospital in Jodhpur, where…

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Jaipur/Kota— In a significant move to strengthen patient safety and improve healthcare delivery in government hospitals, Kota district in-charge secretary Dr. Ravi Kumar Surpur has directed the immediate preparation and effective…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    8 Women Develop Complications Post C-Section, 2 Critical

    8 Women Develop Complications Post C-Section, 2 Critical

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Kota District In-Charge Secretary Directs Implementation of Risk Management Framework in Hospitals; Emphasis on SOPs and Infection Control

    Probe report into maternal deaths sparks Kota row

    Probe report into maternal deaths sparks Kota row

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Centre bans 16 Fixed-Dose Combination drugs over safety concerns

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    Maha FDA seizes medicines worth Rs 9.09 lakh from Mumbai children’s hospital over alleged illegal sale

    CDSCO constitutes consultancy committee for advice on suo motu disclosure

    CDSCO constitutes consultancy committee for advice on suo motu disclosure